BackLigand Pharmaceuticals Overview

Ligand Pharmaceuticals Other Assets

Ligand Pharmaceuticals's other assets is $550M.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$553.90M

Peer trimmed avg / median

Loading

Ligand Pharmaceuticals Other Assets History

Loading

Ligand Pharmaceuticals vs. peers: Other Assets Comparison

Loading

Ligand Pharmaceuticals Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ligand Pharmaceuticals (LGND) FAQ

As of the most recent data (June 2026), LGND shows a other assets of $550M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LGND's other assets is now $550M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Ligand Pharmaceuticals is outperforming or lagging.

Tracking LGND's other assets over time shows whether Ligand Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $550M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Ligand Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $550M) with ownership activity and broader fundamentals.

Ligand Pharmaceuticals's other assets is $550M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.